DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 1, 2023, and May 5, 2023. DarioHealth Corp. (DRIO) entered into material definitive agreements to secure capital through a preferred stock offering and a new credit facility, while simultaneously terminating a prior credit agreement.
Key Financial Metrics and Capital Structure
- Equity Proceeds: The Company raised approximately $15.4 million in gross proceeds from the sale of Series B, B-1, B-2, and B-3 Preferred Stock at $1,000 per share.
- Debt Facility: Entered into a $40 million secured credit facility with Avenue Venture Opportunities Fund. An initial tranche of $30 million was funded on May 1, 2023. A discretionary tranche of up to $10 million may be available later.
- Interest Rates: The loan bears interest at the higher of 4.50% plus the prime rate or 12.50% per annum. A default rate applies at 5.00% above the applicable rate.
- Liquidity Covenant: The Company must maintain at least $5 million of unrestricted cash and cash equivalents at all times.
- Transaction Costs: The Company agreed to pay $410,000 in fees to consultants and finders in Israel.
Material Changes Versus Prior Period
- Debt Restructuring: The funding of the new Avenue Venture Loan satisfied and terminated the Company's prior Credit Agreement with OrbiMed Royalty and Credit Opportunities III, LP, executed on June 9, 2022.
- Capitalization: Issuance of new preferred stock classes (Series B, B-1, B-2, B-3) and warrants to purchase up to 584,882 shares of common stock to lenders.
- Shareholder Agreements: Executed an agreement with Series A-1 Convertible Preferred Stockholders to issue up to 1,273,499 shares of Common Stock in exchange for their agreement not to convert their preferred shares.
Guidance, Outlook, and Risks
- Conversion Terms: Preferred stock converts to common stock at initial prices ranging from $3.334 to $3.392. Automatic conversion occurs on the 15-month anniversary of issuance, subject to a 19.99% beneficial ownership blocker.
- Dividends: Preferred stockholders receive dividends in shares of Common Stock: 5% of issuable shares for each of the first four quarters, and 10% in the fifth quarter.
- Loan Milestones: Monthly payments under the loan facility depend on meeting specific milestones. Failure to meet milestones requires monthly principal installments sufficient to fully amortize the loan.
- Risks: The loan agreement contains customary events of default, including nonpayment, bankruptcy, material adverse effects, and key person events. The agreement restricts the Company's ability to incur additional indebtedness, pay dividends, or dispose of assets.
Investor Verification Checklist
- Verify the exact closing date and final proceeds for the Series B-3 Preferred Stock tranche (expected on or before May 9, 2023).
- Review the specific milestones in the Loan and Security Agreement (LSA) that determine whether interest-only or principal-and-interest payments are required.
- Confirm the dilution impact of the 1,273,499 shares of Common Stock to be issued to Series A-1 holders and the 584,882 warrant shares.
- Monitor the Company's ability to maintain the $5 million unrestricted cash covenant.
- Check for any future equity raises prior to September 30, 2023, which could trigger adjustments to the warrant exercise price.